Where is the treatment of hypertension heading?

Česká verzia

Authors: M. Souček
Authors place of work: II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MU Dr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2013; 59(8): 720-723
Category:

Summary

High normal blood pressure is defined as pressure of 130– 138/ 85– 89 mm Hg. The term prehypertension is used for systolic blood pressure of 120– 139 mm Hg and diastolic pressure of 80– 89 mm Hg. The question is whether blood pressure at those levels should be treated and if so, in which patients. Another question is, whether the therapy can affect the incidence of hypertension and cardiovascular complications.

Key words:
hypertension – high normal blood pressure – cardiovascular complications – pharmacological treatment

Zdroje

1. Filipovský J, Widimský J Jr, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. Hypertenze a kardiovaskulární prevence 2012; 3: 1– 16.

2. Mancia G, Laurent S, Agabiti‑ Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121– 2158.

3. Guidelines Committee. 2003 ESH‑ ESC guidelines for the management od arterial hypertension. J Hypertens 2003; 21: 1011– 1053.

4. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the JNC on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289: 2560– 3257.

5. Widimský J Jr, Cífková R, Spinar J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze. Vnitř Lék 2008; 54: 101– 118.

6. Lewington S, Clarke R, Qizilbash N et al. Prospective Studies Collaboration: Age specific relevance of usual blood pressure to vascular modality: a meta‑analysis of individual data for 1 milion adults in 61 prospective studies. Lancet 2002; 360: 1903– 1913.

7. Hsia J, Margolis KL, Eaton CB et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation 2007; 115: 855– 860.

8. Gu Q, Burt VL, Paulose‑Ram R et al. High blood pressure and cardiovascular disease modality risk among US adults: the Third National Health and Nutrition Examination Surve‑ y Mortality Follow‑up Study. Ann Epidemiol 2008; 18: 302– 309.

9. Dong GH, Wang D, Liu MM et al. Sex difference of the prevalence and risk factors associated with prehypertension aminy urban Chinese adults from 33 communities of China: the CHPSNE study. J Hypertens 2012; 30: 485– 491.

10. Mainous AG, Everett CJ, Liszka H et al. Prehypertension and modality in a nationally representative cohort. Am J Cardiol 2004; 94: 1496– 1500.

11. Glasser SP, Judd S, Basile J et al. Prehypertension, racial prevalence and its association with risk factors: Analysis of the REasons for Geografie and Racial Differences in Stroke (REGARDS) Study. Am J Hypertens 2011; 24: 194– 199.

12. Kim BJ, Lee HJ, Sung KC et al. Comparison of mikroa1buminuria in 2 blood pressure categories of prehypertensive subjects. Circ J 2007; 71: 1283– 1287.

13. Everett CJ, Frithsen IL. Evidence that prehypertension is a risk factor for type 2. diabetes. Expert Rev Cardiovasc Ther 2010; 8: 335– 337.

14. Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117– 1124.

15. Svetkey LP, Simons‑ Morton D, Vollmer WM et al. Effects of dietary patterns on blood subgroup analysis of the dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch intern Med 1999; 159: 285– 293.

16. Slimko ML, Mensah GA. The role of diets, food, and nutrients in the prevention and control of hypertension and prehypertension. Cardiol Clin 2010; 28: 665– 674.

17. Julius S, Nesbitt SD, Egan BM et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin‑receptor blocker. N Engl J Med 2006; 354: 1685– 1697.

18. Liiders S, Schrader J, Berger J et al. The PHARAO Study: Prevention of hypertension with the ACE inhibitor ramipril in patients with high‑normal blood pressure – a prospective randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008; 26: 1487– 1496.

19. Rosolová H. Prehypertenze a vysoký normální krevní tlak. In: Perušičová J (ed). Prediabetes, prehypertenze, dyslipidemie a metabolický syndrom. Praha: Maxdorf 2012: 211– 221.

20. Holman RR, Paul SK, Bethel MA et al. Long‑Term Follow‑up after Tight Control of Blood Pressure in Type 2 Diabetes. N Engl J Med 2008; 359: 1575– 1576.

21. Vasan RS, Larson MG, Leip EP et al. Impact of high‑normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291– 1297.